Skin diseases contribute significantly to morbidity worldwide, yet their burden in North Africa and the Middle East (NAME) remains poorly understood. This study aims to assess the burden of skin ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...